| Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma NP Kristensen, C Heeke, SA Tvingsholm, A Borch, A Draghi, ... The Journal of clinical investigation 132 (2), 2022 | 81 | 2022 |
| T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression R Andersen, TH Borch, A Draghi, A Gokuldass, MAH Rana, M Pedersen, ... Annals of Oncology 29 (7), 1575-1581, 2018 | 69 | 2018 |
| Differential effects of corticosteroids and anti‐TNF on tumor‐specific immune responses: implications for the management of irAEs A Draghi, TH Borch, HD Radic, CA Chamberlain, A Gokuldass, IM Svane, ... International Journal of Cancer 145 (5), 1408-1413, 2019 | 48 | 2019 |
| MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells MJW Peeters, D Dulkeviciute, A Draghi, C Ritter, A Rahbech, ... Cancer immunology research 7 (9), 1472-1484, 2019 | 45 | 2019 |
| Acquired resistance to cancer immunotherapy A Draghi, CA Chamberlain, A Furness, M Donia Seminars in immunopathology 41, 31-40, 2019 | 43 | 2019 |
| Tumor-infiltrating T cells from clear cell renal cell carcinoma patients recognize neoepitopes derived from point and frameshift mutations UK Hansen, S Ramskov, AM Bjerregaard, A Borch, R Andersen, A Draghi, ... Frontiers in immunology 11, 373, 2020 | 34 | 2020 |
| Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8+ T Cells in Non-Melanoma … A Gokuldass, A Draghi, K Papp, TH Borch, M Nielsen, MCW Westergaard, ... Cancers 12 (11), 3344, 2020 | 24 | 2020 |
| Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF® 09b, in patients with metastatic melanoma SK Mørk, M Kadivar, KF Bol, A Draghi, MCW Westergaard, SK Skadborg, ... Oncoimmunology 11 (1), 2023255, 2022 | 21 | 2022 |
| Efficacy of nivolumab in pediatric cancers with high mutation burden and mismatch repair deficiency A Das, U Tabori, LC Sambira Nahum, NB Collins, R Deyell, R Dvir, ... Clinical Cancer Research 29 (23), 4770-4783, 2023 | 19 | 2023 |
| Rapid Identification of the Tumor-Specific Reactive TIL Repertoire via Combined Detection of CD137, TNF, and IFNγ, Following Recognition of Autologous Tumor … A Draghi, CA Chamberlain, S Khan, K Papp, M Lauss, S Soraggi, ... Frontiers in Immunology 12, 705422, 2021 | 18 | 2021 |
| Cancer immunotherapy in patients with brain metastases S Caponnetto, A Draghi, TH Borch, M Nuti, E Cortesi, IM Svane, M Donia Cancer Immunology, Immunotherapy 67, 703-711, 2018 | 16 | 2018 |
| Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R) IM Chen, M Donia, CA Chamberlain, AWP Jensen, A Draghi, S Theile, ... European Journal of Cancer 180, 125-133, 2023 | 14 | 2023 |
| The effects of targeted immune-regulatory strategies on tumor-specific T-cell responses in vitro M Presti, MCW Westergaard, A Draghi, CA Chamberlain, A Gokuldass, ... Cancer Immunology, Immunotherapy 70, 1771-1776, 2021 | 10 | 2021 |
| Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome VAB de Lima, A Borch, M Hansen, A Draghi, I Spanggaard, K Rohrberg, ... Cytotherapy 22 (4), 204-213, 2020 | 10 | 2020 |
| MERTK acts as a costimulatory receptor on human CD8+ T cells. Cancer Immunol Res.(2019) 7: 1472–84. doi: 10.1158/2326-6066 MJW Peeters, D Dulkeviciute, A Draghi, C Ritter, A Rahbech, ... CIR-18-0841.[Abstract][CrossRef][Google Scholar], 0 | 10 | |
| Coexisting alterations of MHC class I antigen presentation and IFNγ signaling mediate acquired resistance of melanoma to post–PD-1 immunotherapy M Nielsen, M Presti, Z Sztupinszki, AWP Jensen, A Draghi, ... Cancer immunology research 10 (10), 1254-1262, 2022 | 9 | 2022 |
| Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF (R) 09b, in patients with metastatic melanoma SK Mork, M Kadivar, KF Bol, A Draghi, MCW Westergaard, SK Skadborg, ... Oncoimmunology 11 (1), 2022 | 7 | 2022 |
| Transcriptomic signatures of tumors undergoing T cell attack A Gokuldass, A Schina, M Lauss, K Harbst, CA Chamberlain, A Draghi, ... Cancer Immunology, Immunotherapy, 1-11, 2022 | 7 | 2022 |
| Uncoupling CD4+ TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma A Draghi, M Presti, AWP Jensen, CA Chamberlain, B Albieri, ... Clinical Cancer Research 29 (19), 3937-3947, 2023 | 5 | 2023 |
| TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy SA Tvingsholm, MS Frej, VM Rafa, UK Hansen, M Ormhøj, A Tyron, ... Journal for immunotherapy of cancer 11 (8), 2023 | 5 | 2023 |
